^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SGN-STNV

    i
    Other names: SGN-STNV
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    Microtubule inhibitor, STn-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    2ms
    SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=111, Terminated, Seagen Inc. | Trial completion date: Mar 2026 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Mar 2024; Study closed due to portfolio prioritization
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    SGN-STNV
    7ms
    SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=111, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting | N=360 --> 111
    Enrollment closed • Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    SGN-STNV
    over1year
    SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=315, Recruiting, Seagen Inc. | Trial completion date: Dec 2023 --> Mar 2026 | Trial primary completion date: Dec 2022 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    SGN-STNV
    almost2years
    SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=315, Recruiting, Seagen Inc. | N=225 --> 315
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    SGN-STNV
    3years
    [VIRTUAL] Targeting Sialyl-Thomsen nouveau (STn) antigen with the SGN-STNV antibody-drug conjugate is effective in preclinical studies (AACR 2021)
    SGN-STNV was well tolerated in non-human primates (NHP), with no concerning target-mediated toxicities and a maximum tolerated dose similar to other vedotin-platform ADCs. In summary, the antibody specificity, unique mechanism of targeting a carbohydrate, anti-tumor activity, and tolerability provide a strong rationale for initiation of a phase I study to investigate the therapeutic potential of SGN-STNV.
    Preclinical
    |
    MUC1 (Mucin 1) • MUC16 (Mucin 16, Cell Surface Associated) • CD44 (CD44 Molecule) • MUC5AC (Mucin 5AC)
    |
    SGN-STNV
    over3years
    SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=205, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    SGN-STNV
    over3years
    SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=205, Not yet recruiting, Seagen Inc.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    SGN-STNV